Du är här

2015-10-06

Active Biotech: Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress

Lund, October 6, 2015 -
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the collaboration
partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will
present data on laquinimod, an investigational therapy being evaluated in
relapsing and progressive forms of MS, at the 31stEuropean Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona,
October 7-10, 2015.

For further information, please seewww.tevapharm.com.

About Laquinimod

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator
with a novel mechanism of action being developed for the treatment of
relapsing-remitting MS (RRMS), progressive MS and Huntington's disease. The
global, Phase III, clinical development program evaluating laquinimod in MS
includes two completed pivotal studies, ALLEGRO and BRAVO (both 0.6mg/day). A
third Phase III trial, CONCERTO, is currently ongoing and evaluating two
doses of laquinimod (0.6mg and 1.2mg/day) in 2,199 patients for up to 24
months. The primary outcome measure is time to three-month
confirmed-disability progression as measured by the Expanded Disability
Status Scale (EDSS).

For further information, please contact:

Tomas Leanderson, President&CEO
Tel +46 46 19 20 95
Email:tomas.leanderson@activebiotech.com

Hans Kolam, CFO
Tel +46 46 19 20 44
Email:hans.kolam@activebiotech.com

Active Biotech AB
(publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally
administered small molecule with unique immunomodulatory properties, is in
pivotal phase III development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in phase II development for the
treatment of primary progressive multiple sclerosis and Huntington's disease.
Furthermore, commercial activities are ongoing for the projects ISI, ANYARA
and paquinimod. Please visitwww.activebiotech.comfor more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or
the Financial Instruments Trading Act
. This information was provided to the media for publication at 2:00 p
.m. CEST on Oct 6, 2015.

Active Biotech’s partner Teva presents data on laquinimod
http://hugin.info/1002/R/1956964/712899.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#1956964

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.